



ASX Release

Jayex operating update

HIGHLIGHTS

- Over \$460,000 in sales in November - a record month
- Increasing efficiencies through upskilling employees and management re-organisation
- Full sales team back on board after being furloughed due to COVID-19
- Appointment of BioAgronomics Group in New Zealand in anticipation of granting of Commercial Cultivation Licence in first quarter of 2021

Melbourne, Australia; 16 December 2020: Jayex Healthcare Limited (ASX: JHL) (**Jayex** or **Company**), a leading UK and Australian e-health provider of integrated SaaS healthcare services delivery platforms, is pleased to give an operating update.

November was a record sales month with over \$460,000 of sales coming equally from GP (Primary) and Hospitals (Acute) areas. The overall UK market is showing signs of recovery as the COVID-19 vaccine is rolled out and Jayex expects the healthcare market to return to usual trading in the latter half of 2021. The Australian market was also strong on the back of state COVID suppression strategies.

It has been a year of consolidation at Jayex as the Company took advantage of the slowdown caused by Covid-19 and the lack of regular corporate activity, to examine and reorganize its operations. The Company used the time to increase efficiencies, retrain and upskill employees and complete a management re-organisation focused on increasing the speed to market for our products.

Jayex's sales team members are now back full time after being furloughed for the past few months due to Covid-19 and the resulting downturn in trading. The sales team have expanded into a new segment for Jayex, NHS Community. NHS Community spends around £10b annually from the NHS budget making this a significant opportunity. Jayex has not previously marketed to this segment and its products are a natural fit in each of the sectors of physiotherapy, mental health and dentistry, etc. opening up a new growth avenue for the Company.

Cannabis

As Jayex's wholly owned subsidiary Whakaora Hou Ltd prepares for an anticipated Commercial Cultivation License in the first quarter of 2021, they have appointed BioAgronomics Group (BioAgronomics). BioAgronomics will both advise and lead the project in all areas related to genetics, breeding and horticulture. Co-founder, notable author and ethnobotanist Robert C. Clarke will lead Research while partner Mojave Richmond will be responsible for breeding and cultivation.

BioAgronomics was established with the goal of using their decades of experience to provide clarity, guidance and assistance in the emerging international cannabis industry. Jayex are delighted to have them on board and their appointment is both practical and strategic in connecting Jayex directly to what is happening within the industry globally.

-Ends-

Jayex Healthcare Limited
(ACN 119 122 477)

Level 4, 100 Albert Road, South Melbourne, VIC, 3205
T | +61 3 9692 7222 W | <https://www.jayex.com/en-au/>

Contacts for further information:

Executive Chairman

Michael Boyd
m.boyd@jayex.com
+44 (0) 731 210 6490

Media & Investor Relations

Kyahn Williamson
WE Communications
kwilliamson@we-worldwide.com
0401 018 828

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Jayex Connect* – the complete cloud-based Patient Engagement Platform;
- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*® remote pharmacy prescription processing and dispensing terminal.

Jayex Healthcare Limited
(ACN 119 122 477)

Level 4, 100 Albert Road, South Melbourne, VIC, 3205
T | +61 3 9692 7222 W | <https://www.jayex.com/en-au/>